Renee D. Gala

Renee D. Gala

DirectoratJazz Pharmaceuticals· In proxies 2023–2025

Pay in FY2025+189% from the year before · Jazz Pharmaceuticals stock +38.0% the same year

Renee D. Gala was paid $19.2M in FY2025 (Dec), up 189%. Jazz Pharmaceuticals stock rose 38.0% that year.

Pay$100 in the stock at the end of FY22 → $107
Pay is from the Summary Compensation Table of each Jazz Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. DexcomPublic company · 1 yr
    • Director2025 – Present · 1 yrNo stock prices for these years
  2. Jazz PharmaceuticalsPublic company · 3 yr
    • President, CEO and Director2023 – Present · 3 yrStock in role +29%

Roles come from the proxy statements of each company.

Boards1

  • Jazz PharmaceuticalsDirector · 0 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?